Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Oral alpha adrenoceptor blockade as a treatment of erectile dysfunction
Autore:
Andersson, KE; Stief, C;
Indirizzi:
Univ Lund Hosp, Dept Clin Pharmacol, S-22185 Lund, Sweden Univ Lund Hosp Lund Sweden S-22185 Clin Pharmacol, S-22185 Lund, Sweden Hannover Med Sch, Dept Urol, D-3000 Hannover, Germany Hannover Med Sch Hannover Germany D-3000 Urol, D-3000 Hannover, Germany
Titolo Testata:
WORLD JOURNAL OF UROLOGY
fascicolo: 1, volume: 19, anno: 2001,
pagine: 9 - 13
SICI:
0724-4983(200102)19:1<9:OAABAA>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
CAVERNOSUM SMOOTH-MUSCLE; PENILE CORPUS CAVERNOSUM; ALPHA(1)-ADRENOCEPTOR SUBTYPES; DOUBLE-BLIND; YOHIMBINE HYDROCHLORIDE; PSYCHOGENIC IMPOTENCE; RECEPTORS; TRIAL; ALPHA(2)-ADRENOCEPTORS; PHENTOLAMINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
46
Recensione:
Indirizzi per estratti:
Indirizzo: Andersson, KE Univ Lund Hosp, Dept Clin Pharmacol, S-22185 Lund, Sweden Univ Lund Hosp Lund Sweden S-22185 l, S-22185 Lund, Sweden
Citazione:
K.E. Andersson e C. Stief, "Oral alpha adrenoceptor blockade as a treatment of erectile dysfunction", WORLD J URO, 19(1), 2001, pp. 9-13

Abstract

The sympathetic nervous system, via release of noradrenaline (NA) and stimulation of a adrenoceptors (ARs), is considered to be the prime determinantof cavernosal smooth muscle contraction and detumescence. A relative predominance of NA-induced contraction over nitric oxide-mediated relaxation maycontribute to erectile dysfunction (ED). Therefore alpha AR antagonism seems an attractive way of treating ED, but so far the therapeutic success of oral treatment has been limited. Modest activity has been documented for the alpha (2) AR antagonist, yohimbine, which is believed to act in the central nervous system. Phentolamine, mainly blocking alpha (1) and alpha (2) ARs peripherally, has been shown to have beneficial effects, but the efficacycompared to other alternatives, e.g., sildenafil, has not been established. To improve oral treatment of ED with alpha AR antagonists, new drugs are required. However, little is known about central noradrenergic mechanisms involved in erection, or which alpha AR subtypes in the penile erectile tissues are the most important for mediation of contraction. It is still unclear what profile (alpha (1) vs alpha (2) ARs; selectivity for alpha (1) and/or alpha (2) AR subtypes) is the most advantageous for an alpha AR antagonist in the treatment of ED.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 03:20:25